1.95  0.05 (2.63%)		08-01 00:00
Open: 1.91 High: 1.97 Volume: 272,208		Pre. Close: 1.9 Low: 1.86 Market Cap: 70(M)

Short term
Mid term
Targets	6-month :	2.3	1-year :	2.68
Resists	First :	1.97	Second :	2.3
Pivot price	1.95
Supports	First :	1.9	Second :	1.86
MAs	MA(5) :	1.95	MA(20) :	1.95
	MA(100) :	1.96	MA(250) :	4.62
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	81.8	D(3) :	81.8
RSI	RSI(14): 60.2
52-week	High :	14.68	Low :	1.26

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CRTX ] has closed Bollinger Bands are 100% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 24 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	1.97 - 1.98	1.98 - 1.99
Low:	1.84 - 1.85	1.85 - 1.86
Close:	1.93 - 1.95	1.95 - 1.97

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Wed, 27 Jul 2022
CRTX stock on watch as company plans name change (NASDAQ:CRTX) - Seeking Alpha

Wed, 27 Jul 2022
Cortexyme Successfully Completes Phase 1 Single and Multiple Ascending Dose Clinical Trial of COR588 - Business Wire

Wed, 27 Jul 2022
Cortexyme Corporate Name Change to Quince Therapeutics to Take Effect on August 1, 2022 - Business Wire

Fri, 20 May 2022
Cortexyme Successfully Completes Acquisition of Novosteo - Business Wire

Mon, 11 Apr 2022
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cortexyme, Inc. - CRTX - PR Newswire

Thu, 23 Dec 2021
Cortexyme (CRTX) stock forecast: Can the drug maker recover? - Capital.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	36 (M)
Shares Float	21 (M)
Held by Insiders	24.5 (%)
Held by Institutions	40.4 (%)
Shares Short	3,670 (K)
Shares Short P.Month	4,510 (K)

EPS	-2.97
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	3.52
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-37.5 %
Return on Equity (ttm)	-67.4 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-2.41
Qtrly Earnings Growth	0 %
Operating Cash Flow	-65 (M)
Levered Free Cash Flow	-32 (M)

PE Ratio	-0.66
PEG Ratio	-0.1
Price to Book value	0.55
Price to Sales	0
Price to Cash Flow	-1.08

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.